Spectrum Pharma: Zevalin Has Blockbuster Potential - trackseekingalpha

Sign Up | Log In | What is SocialPicks?

Spectrum Pharma: Zevalin Has Blockbuster Potential
Oct 25, 2009 11:41 AM UTC

trackseekingalpha

Return	Risk
-11.17%	HIGH

Tracked Blogger

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
SPPI	n/a
RIT	n/a

Via Long Investment Ideas from Seeking Alpha:

A number of positive peer-reviews evaluating Spectrum Pharmaceuticals (SPPI) radio-immunotherapy (RIT), Zevalin® were published this month. The conclusions drawn in these reviews were made from unbiased medical professionals, and indicate that the prospects for Zevalin may be greater than I originally estimated back on <font>June 12</font>.

Based on the feedback received from a doctor whose opinion I value, I now believe Zevalin has blockbuster potential. In general, blockbuster drugs typically generate annual revenue of $1 billion or greater.

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.